

# Calendar Year 2011 Annual Review of Xopenex® (levalbuterol) Nebulizer Solution

## Prior Authorization Criteria

Prior authorization is not required for a total duration of 90 days per every 365 days. Use of this product in excess of 90 days of therapy in a 360 day period will require a prior authorization that includes:

1. Reason member is unable to use long acting bronchodilators and/or inhaled corticosteroid (ICS) therapy for long-term control as recommended in the NAEPP guidelines.
2. Also the need for use of this product over an albuterol MDI should be stated.
3. Clinical exceptions will be made for clients with COPD.
4. Quantity Limit of 288mls per 30 days will also apply.

## Utilization of Levalbuterol

### Utilization Trends


Calendar Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2010	6,239	10,774	\$2,043,575.90	\$189.68	\$10.86	1,446,078	188,114
2011	5,083	8,719	\$1,917,910.04	\$219.97	\$12.51	1,192,414	153,283
<b>Percent Change</b>	<b>-18.50%</b>	<b>-19.10%</b>	<b>-6.10%</b>	<b>16.00%</b>	<b>15.20%</b>	<b>-17.50%</b>	<b>-18.50%</b>
<b>Change</b>	<b>-1,156</b>	<b>-2,055</b>	<b>-\$125,665.86</b>	<b>\$30.29</b>	<b>\$1.65</b>	<b>-253,664</b>	<b>-34,831</b>

### Utilization Details CY 2011


Brand Name	Claims	Members	Days	Cost	Perdiem	Claims/Member	% Cost
XOPENEX® NEB 0.63MG	4,245	2,579	75,590	\$962,693.83	\$12.74	1.65	50.19%
XOPENEX® NEB 1.25/3ML	2,295	1,267	41,483	\$524,639.27	\$12.65	1.81	27.35%
XOPENEX® NEB 0.31MG	2,143	1,442	35,487	\$422,466.42	\$11.90	1.49	22.03%
LEVALBUTEROL NEB 1.25/0.5	35	28	718	\$7,943.35	\$11.06	1.25	0.41%
XOPENEX® CONC NEB 1.25/0.5	1	1	5	\$167.17	\$33.43	1	0.01%
<b>Total</b>	<b>8,719</b>	<b>5,083*</b>	<b>153,283</b>	<b>\$1,917,910.04</b>	<b>\$12.51</b>	<b>1.72</b>	<b>100.00%</b>

\*Unduplicated total number of members.

### Demographics of Members Utilizing Levalbuterol for FY 2010



## Prescriber Specialty by Number of Claims for CY 2011




## Prior Authorization of Levalbuterol

---

There were a total of 484 petitions submitted for this PBPA category during Calendar Year 2011. The following chart shows the status of the submitted petitions.

### Status of Petitions for Osteoporosis Medications: FY 2010



## Market News and Update

---

The first patents for Xopenex<sup>®</sup> expired in January 2010. However, due to manufacturer negotiations, the only Xopenex<sup>®</sup> product available in generic formulation is the concentrated Xopenex<sup>®</sup> 1.25mg/0.5mL, which utilization data showed minimal use during calendar year 2011. The next Xopenex<sup>®</sup> patent is set to expire in March 2013.

## Conclusions

---

The College of Pharmacy recommends no changes to this category at this time.